104 related articles for article (PubMed ID: 11877751)
1. Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry.
Hindorf C; Lindén O; Tennvall J; Wingårdh K; Strand SE
Cancer; 2002 Feb; 94(4 Suppl):1235-9. PubMed ID: 11877751
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
Hindorf C; Lindén O; Tennvall J; Wingårdh K; Strand SE
Acta Oncol; 2005; 44(6):579-88. PubMed ID: 16165917
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
[TBL] [Abstract][Full Text] [Related]
4. Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs.
Larsson E; Ljungberg M; Martensson L; Nilsson R; Tennvall J; Strand SE; Jonsson BA
Med Phys; 2012 Jul; 39(7):4434-43. PubMed ID: 22830776
[TBL] [Abstract][Full Text] [Related]
5. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy.
Siegel JA; Lee RE; Pawlyk DA; Horowitz JA; Sharkey RM; Goldenberg DM
Int J Rad Appl Instrum B; 1989; 16(6):553-9. PubMed ID: 2481657
[TBL] [Abstract][Full Text] [Related]
6. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.
Ferrer L; Kraeber-Bodéré F; Bodet-Milin C; Rousseau C; Le Gouill S; Wegener WA; Goldenberg DM; Bardiès M
Cancer; 2010 Feb; 116(4 Suppl):1093-100. PubMed ID: 20127958
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow dosimetry using 124I-PET.
Schwartz J; Humm JL; Divgi CR; Larson SM; O'Donoghue JA
J Nucl Med; 2012 Apr; 53(4):615-21. PubMed ID: 22414633
[TBL] [Abstract][Full Text] [Related]
8. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
Boucek JA; Turner JH
Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
10. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody.
Siegel JA; Pawlyk DA; Lee RE; Sasso NL; Horowitz JA; Sharkey RM; Goldenberg DM
Cancer Res; 1990 Feb; 50(3 Suppl):1039s-1042s. PubMed ID: 2297717
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
[TBL] [Abstract][Full Text] [Related]
12. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
Behr TM; Béhé M; Sgouros G
Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708
[TBL] [Abstract][Full Text] [Related]
13. Blood-based red marrow dosimetry: where's the beef?
Siegel JA; Sparks RB; Sharkey RM; Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Meredith RF; Sgouros G; Stabin MG
J Nucl Med; 2005 Aug; 46(8):1404-6; author reply 1405-6. PubMed ID: 16085600
[No Abstract] [Full Text] [Related]
14. Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies.
Plaizier MA; Roos JC; Teule GJ; van Dieren EB; den Hollander W; Haisma HJ; DeJager RL; van Lingen A
Eur J Nucl Med; 1994 Mar; 21(3):216-22. PubMed ID: 8200389
[TBL] [Abstract][Full Text] [Related]
15. Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients.
Hindorf C; Lindén O; Stenberg L; Tennvall J; Strand SE
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):4003S-6S. PubMed ID: 14506200
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
[TBL] [Abstract][Full Text] [Related]
17. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
[TBL] [Abstract][Full Text] [Related]
18. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
19. Distribution of a breast-directed I-131-radiolabeled monoclonal antibody in blood and bone marrow: implications for radiation immunotherapy.
Johnson TK; Gonzalez R; Kasliwal RK; Lear JL; Feyerabend AJ; Dienhart DG; Ceriani RL; Bunn PA
Radiology; 1992 Jan; 182(1):107-14. PubMed ID: 1727271
[TBL] [Abstract][Full Text] [Related]
20. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
